The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

Diabetes Care

Volumn 27, Issue 8, 2004, Pages 1915-1921

  Harder, Helle ^a   Nielsen, Lene ^b   Thi, Tu D T ^b   Astrup, Arne ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; LIRAGLUTIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LEAN BODY WEIGHT; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PLACEBOS;

EID: 3342984674     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.8.1915     Document Type: Article

References (31)

1. Nauck MA, Holst JJ, Willms B, Schmiegel W: Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187-195, 1997
2. Holst JJ: Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107:1848-1855, 1994
3. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304, 1987
4. Unger RH, Eisentraut AM: Entero-insular axis. Arch Intern Med 123:261-266, 1969
5. Larsson H, Holst JJ, Ahren B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422, 1997
6. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520, 1998
7. Drucker DJ: Glucagon-like peptides. Diabetes 47:159-169, 1998
8. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM: Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311, 1999
9. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM: Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68:525-530, 1998
10. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V: Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38:916-919, 1996
11. Naslund E, Gryback P, Backman L, Jacobsson H, Holst JJ, Theodorsson E, Hellstrom PM: Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 43:945-952, 1998
12. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276: R1541-R1544, 1999
13. Toft-Nielsen MB, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143, 1999
14. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W: Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21:192-1931, 1998
15. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
16. Knudsen LB, Agerso H, Bjenning S, Bregenholt S, Carr RD, Godtfredsen C, Holst JJ, Huusfeldt PO, Larsen MO, Larsen PJ, Nielsen PF, Ribel U, Rolin B, Romer J, Sturis J, Wilken M, Kristensen P: GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: selection of NN2211 for clinical development. Drugs of the Future 26:677-685, 2001
17. Flint A, Raben A, Blundell JE, Astrup A: Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 24:38-48, 2000
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
19. Toubro S, Sorensen TI, Ronn B, Christensen NJ, Astrup A: Twenty-four-hour energy expenditure: the role of body composition, thyroid status, sympathetic activity, and family membership. J Clin Endocrinol Metab 81:2670-2674, 1996
20. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
21. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165-175, 1998
22. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM: Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 45:1684-1693, 1996
23. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27:1335-1342, 2004
24. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530-2539, 2001
25. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brnad CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB: GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140:123-132, 2003
26. Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 26:1902-1912, 2003
27. Kieffer TJ, Habener JF: The glucagon-like peptides. Endoctine Rev 20:876-913, 1999
28. Weir GC, Mojsov S, Hendrick GK, Habener JF: Glucagonlike peptide 1 (7-37) actions on endocrine pancreas. Diabetes 38:338-342, 1989
29. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB: The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52:1786-1791, 2003
30. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
31. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and post-prandial glycemia in type 2 diabetes. Diabetes 51:424-429, 2002